Moderna 的新冠-流感组合疫苗在后期试验中表现出更高的免疫反应，可能在今年获得 NHS 批准。 Moderna's Covid-flu combo vaccine shows higher immune responses in late-stage trial, potentially leading to NHS approval this year.

Moderna 的新冠-流感联合疫苗在后期临床试验中表现出比单独注射更高的免疫反应，这可能为其今年获得批准并在 NHS 中使用铺平了道路。 Moderna's Covid-flu combination vaccine has shown higher immune responses in a late-stage clinical trial than separate single jabs, potentially paving the way for its approval and use on the NHS this year. 该结果标志着联合疫苗的最终第 3 阶段数据首次公布，该疫苗由 Moderna 的 Spikevax 新冠疫苗与辉瑞/BioNTech 的 Comirnaty 疫苗一起用于 NHS 加强计划。 The results mark the first time final phase 3 data has been published for a combined vaccine, with Moderna's Spikevax vaccine for Covid-19 used in the NHS booster programmes alongside Pfizer/BioNTech's Comirnaty.